Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Swasti Wagh

Swasti Wagh

Precedent of Indore Chapter of SAMAG (Seek a Miracle Ataxia Group), India

Title: Magnetic nanoparticle/ magnetic fluid approach to control neuromuscular degeneration in Friedreich’s ataxia

Biography

Biography: Swasti Wagh

Abstract

In last two decades nanotechnology has brought a revolution in the advancement of material science, biology, biotechnology, genetics, medicine and many other areas of science and engineering. The ability of nanotechnologist to prepare material particles of nano size, coating them with a suitable surfactant and magnetizing these particles has made possible to study micro level biological entities such as cells, genes and proteins. In recent years magnetic nanoparticles have been used in cancer treatment, drug delivery and in many other medical fields. This leads us to think why this technology should not be introduced in F.A. research for which no treatment is available and patients suffer with lethal neuro- degenerarative condition of F.A. making them totally dependent on others for even the simple day to day activities. The disease is genetic and unknowingly passes on in off-springs through the carrier parents. It is therefore necessary to control degeneration in F.A. patients and make their life comfortable. Friedreich’s ataxia (FRDA) is an autosomal recessive inherited disease caused by (GAA) expansion of the FXN (frataxin) gene. FRDA is predominantly a neurodegenerative disease. It manifests in initial symptoms of poor coordination such as gait disturbance; it can also lead to scoliosis, heart disease (cardiomyopathy) and diabetes. FXN gene produces frataxin protein which is localized to the mitochondria. The function of FXN is not entirely clear, however, the primary role of FXN protein is the activation of iron-sulfur (Fe-S) cluster biogenesis in the mitochondria. In F.R.D.A. production of FXN protein is reduced. In affected individuals level of FXN drops approximately 5 to 30% than healthy individuals. The role of FXN protein is that of an iron chaperone, a companion of iron particle. Low FXN levels lead to insufficient biosynthesis of iron-sulfur clusters that are required for mitochondrial electron transport chain to ultimately generate adenosine triphosphate (ATP), the energy packet necessary to carry out metabolic functions in cells. FXN also regulates iron transfer in the mitochondria in order to provide a proper amount of reactive oxygen species (ROS) to maintain normal processes
without FXN, the energy in the mitochondria falls, and excess iron causes extra ROS to be created, leading to further cell damage. Nanotechnology can be useful to solve this problem. We can introduce body compatible magnetic nanoparticles to pickup iron particles and direct them to sulpher to form iron-sulpher clusters. Thus iron-sulpher clusters can be formed even in the absence of FXN protein in F.A. patients. And thus the process of respiration in mitochondria will continue to produce energy in the form of ATP. As iron particles are utilized in formation of iron-sulpher clusters no free iron is left to get deposited on cells and cause cell death in FRDA patents.